Lauren R. Desrosiers-Battu,Tao Wang,Jacquelyn Reuther,George Miles,Hongzheng Dai,Eunji Jo,Heidi Russell,Robin Raesz-Martinez,Alva Recinos,Stephanie Gutierrez,Amy Thomas,Emily Berenson,Jessica Corredor,Kimberly Nugent,Rachel Wyatt Castillo,Rebecca Althaus,Rebecca Littlejohn,Shawn Gessay,Gail Tomlinson,Jonathan Gill,Juan Carlos Bernini,Kelly Vallance,Timothy Griffin,Sarah Scollon,Frank Y. Lin,Christine Eng,Shashikant Kulkarni,Susan G. Hilsenbeck,Angshumoy Roy,Amy L. McGuire,D. Williams Parsons,Sharon E. Plon

Abstract:PURPOSE To evaluate the relative diagnostic yield of clinical germline genomic tests in a diverse pediatric cancer population. PATIENTS AND METHODS The KidsCanSeq study enrolled pediatric cancer patients across six sites in Texas. Germline analysis included both exome sequencing and a therapy-focused pediatric cancer gene panel. The results were categorized by participants demographics, the presence of pathogenic or likely pathogenic (P/LP) variants, and variants of uncertain significance (VUS) in cancer predisposition genes (CPGs). Pediatric actionable CPGs were defined as those with cancer surveillance recommendations during childhood. RESULTS Cancer P/LP variants were reported by at least one platform in 103 of 578 (17.8%) participants of which 76 were dominant cancer genes (13.1%) with no significant differences by self-described race or Hispanic ethnicity. However, the proportion of participants with VUS was greater in Asian and African American participants ( P = .0029). Diagnostic yield was 16.6% for exome versus 8.5% for panel ( P < .0001) with 42 participants with concordant germline results. Exome-only results included P/LP variants in 30 different CPGs in 54 participants, whereas panel-only results included seven participants with a copy number or structural P/LP variants in CPGs. There was no significant difference in diagnostic yield limited to pediatric actionable CPGs ( P = .6171). CONCLUSION Approximately 18% of a diverse pediatric cancer population had germline diagnostic findings with 50% of P/LP variants reported by only one platform because of CPGs not on the targeted panel and copy number variants (CNVs)/rearrangements not reported by exome. Although diagnostic yields were similar in this diverse population, increases in VUS results were observed in Asian and African American populations. Given the clinical significance of CNVs/rearrangements in this cohort, detection is critical to optimize germline analysis of pediatric cancer populations.

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Uncovering recessive alleles in rare Mendelian disorders by genome sequencing of 174 individuals with monoallelic pathogenic variants

Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis

A Copernican Revolution of Multigenic Analysis: A Retrospective Study on Clinical Exome Sequencing in Unclear Genetic Disorders

Structural and non-coding variants increase the diagnostic yield of clinical whole genome sequencing for rare diseases

Next-generation diagnostics: gene panel, exome, or whole genome?

Clinical exome sequencing in the diagnosis of pediatric neuromuscular disease

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Beyond the exome: what's next in diagnostic testing for Mendelian conditions

Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

Clinical application of whole-exome sequencing across clinical indications

Narrowing the Diagnostic Gap: Genomes, Episignatures, Long-Read Sequencing and Health Economic Analyses in an Exome-Negative Intellectual Disability Cohort

Exome and genome sequencing in a heterogeneous population of patients with rare disease: Identifying predictors of a diagnosis

Clinical exome sequencing data from patients with inborn errors of immunity: Cohort level diagnostic yield and the benefit of systematic reanalysis

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome data

Beyond Single Diagnosis: Exploring Multidiagnostic Realities in Pediatric Patients through Genome Sequencing

Increased Diagnostic Yield by Reanalysis of Whole Exome Sequencing Data in Mitochondrial Disease

Long-read genome sequencing and variant reanalysis increase diagnostic yield in neurodevelopmental disorders

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test